Pharmacokinetics, biocompatibility and bioavailability of a controlled release monoclonal antibody formulation

Journal of Controlled Release

Volumn 172, Issue 3, 2013, Pages 975-982

  Schweizer, Daniel ^a   Vostiar, Igor ^a   Heier, Annabelle ^a   Serno, Tim ^a   Schoenhammer, Karin ^a   Jahn, Michael ^a   Jones, Stewart ^a   Piequet, Aline ^a   Beerli, Christian ^a   Gram, Hermann ^a   Goepferich, Achim ^b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Alginate; Antibody; Bioavailability; Biocompatibility; Controlled release; Pharmacokinetics

Indexed keywords

ALGINATE; ANIMALS; ANTIBODIES; BIOCHEMISTRY; BIOCOMPATIBILITY; HYDROGELS; MONOCLONAL ANTIBODIES; PHARMACOKINETICS; TARGETED DRUG DELIVERY; TISSUE;

BIOAVAILABILITY; CONTROLLED RELEASE; CONTROLLED RELEASE SYSTEMS; HUMAN MONOCLONAL ANTIBODIES; MONOCLONAL ANTIBODIES (MABS); MULTIPLE COMPARTMENTS; PHARMACOKINETIC PROFILES; SUBCUTANEOUS TISSUES;

CONTROLLED DRUG DELIVERY;

ALGINIC ACID; CALCIUM; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY IGG1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BIOCOMPATIBILITY; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; CROSS LINKING; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG HALF LIFE; DRUG TISSUE LEVEL; HYDROGEL; INJECTION; LIQUID; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PHARMACOLOGICAL PARAMETERS; PRIORITY JOURNAL; RAT; SUBCUTANEOUS TISSUE; SUSTAINED DRUG RELEASE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ALGINATE; ANTIBODY; BIOAVAILABILITY; BIOCOMPATIBILITY; CONTROLLED RELEASE; PHARMACOKINETICS;

ALGINATES; ANIMALS; ANTIBODIES, MONOCLONAL; BIOLOGICAL AVAILABILITY; DELAYED-ACTION PREPARATIONS; GLUCURONIC ACID; HEXURONIC ACIDS; HUMANS; HYDROGEL; IMMUNOGLOBULIN G; INJECTIONS, SUBCUTANEOUS; MALE; RATS; RATS, WISTAR;

EID: 84887135712     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2013.10.010     Document Type: Article

References (38)

1. T. Yasukawa, Y. Tabata, H. Kimura, and Y. Ogura Ocular drug delivery for bioactive proteins Expert Rev. Ophthalmol. 6 2011 657 667
2. J.L. Kovach, S.G. Schwartz, H.W. Flynn Jr., and I.U. Scott Anti-VEGF treatment strategies for wet AMD J. Ophthalmol. 2012 2012
3. D.M. Urech, U. Feige, S. Ewert, V. Schlosser, M. Ottiger, K. Polzer, G. Schett, and P. Lichtlen Anti-inflammatory and cartilage-protecting effects of an intra-articularly injected anti-TNF alpha single-chain Fv antibody (ESBA105) designed for local therapeutic use Ann. Rheum. Dis. 69 2010 443 449
4. S. Cohen, S. Proudman, A. Kivitz, F. Burch, J. Donohue, D. Burstein, Y.N. Sun, C. Banfield, M. Vincent, L. Ni, and D. Zack A randomized, double-blind study of AMG 108 (a fully human monoclonal antibody to IL-1R1) in patients with osteoarthritis of the knee Arthritis Res. Ther. 13 2011 R125
5. N. Gerwin, C. Hops, and A. Lucke Intraarticular drug delivery in osteoarthritis Adv. Drug Deliv. Rev. 58 2006 226 242
6. C. Larsen, J. Ostergaard, S.W. Larsen, H. Jensen, S. Jacobsen, C. Lindegaard, and P.H. Andersen Intra-articular depot formulation principles: role in the management of postoperative pain and arthritic disorders J. Pharm. Sci. 97 2008 4622 4654
7. K. Hopkins, and J. Kemshead Progress review: intrathecal and intratumoral injection of radiolabeled Monoclonal Antibodies (MoAbs) for the treatment of Central Nervous System (CNS) malignancies J. Drug Target. 1 1993 175 183 (Pubitemid 2022690)
8. R.G. Soderquist, and M.J. Mahoney Central nervous system delivery of large molecules: challenges and new frontiers for intrathecally administered therapeutics Expert Opin. Drug Deliv. 7 2010 285 293
9. A.L. Daugherty, L.K. Rangell, R. Eckert, J. Zavala-Solorio, F. Peale, and R.J. Mrsny Sustained release formulations of rhVEGF165 produce a durable response in a murine model of peripheral angiogenesis Eur. J. Pharm. Biopharm. 78 2011 289 297
10. E. Horisawa, T. Hirota, S. Kawazoe, J. Yamada, H. Yamamoto, H. Takeuchi, and Y. Kawashima Prolonged Anti-Inflammatory action of DL-lactide/glycolide copolymer nanospheres containing betamethasone sodium phosphate for an intra-articular delivery system in antigen-induced arthritic rabbit Pharm. Res. 19 2002 403 410 (Pubitemid 34408936)
11. K.M. Sampat, and S.J. Garg Complications of intravitreal injections Curr. Opin. Ophthalmol. 21 2010
12. B. Pal, and J. Morris Perceived risks of joint infection following intra-articular corticosteroid injections: a survey of rheumatologists Clin. Rheumatol. 18 1999 264 265 (Pubitemid 29284730)
13. C. Kaiser, A. Knight, D. Nordstroem, T. Pettersson, J. Fransson, E. Florin-Robertsson, and B. Pilstroem Injection-site reactions upon Kineret (anakinra) administration: experiences and explanations Rheumatol. Int. 32 2012 295 299
14. S.D. Putney, and P.A. Burke Improving protein therapeutics with sustained-release formulations Nat. Biotechnol. 16 1998 153 157 (Pubitemid 128723585)
15. F. Wu, and T. Jin Polymer-based sustained-release dosage forms for protein drugs, challenges, and recent advances AAPS PharmSciTech 9 2008 1218 1229
16. W. Jiskoot, T.W. Randolph, D.B. Volkin, C.R. Middaugh, C. Schoeneich, G. Winter, W. Friess, D.J.A. Crommelin, and J.F. Carpenter Protein instability and immunogenicity: roadblocks to clinical application of injectable protein delivery systems for sustained release J. Pharm. Sci. 101 2012 946 954
17. D. Schweizer, K. Schoenhammer, M. Jahn, and A. Goepferich Protein-polyanion interactions for the controlled release of monoclonal antibodies Biomacromolecules 14 2013 75 83
18. K.I. Draget, K. Ostgaard, and O. Smidsrod Alginate-based solid media for plant-tissue culture Appl. Microbiol. Biotechnol. 31 1989 79 83
19. K.I. Draget, K. Ostgaard, and O. Smidsrod Homogeneous alginate gels - a technical approach Appl. Microbiol. Biotechnol. 14 1990 159 178 (Pubitemid 21736289)
20. R. Baker Controlled release of biologically active agents 1987 John Wiley & Sons New York
21. C. Guse, S. Koennings, A. Maschke, M. Hacker, C. Becker, S. Schreiner, T. Blunk, T. Spruss, and A. Goepferich Biocompatibility and erosion behavior of implants made of triglycerides and blends with cholesterol and phospholipids Int. J. Pharm. 314 2006 153 160
22. B.F. Matlaga, L.P. Yasenchak, and T.N. Salthouse Tissue response to implanted polymers: the significance of sample shape J. Biomed. Mater. Res. 10 1976 391 397
23. E.A. Nunamaker, E.K. Purcell, and D.R. Kipke In vivo stability and biocompatibility of implanted calcium alginate disks J. Biomed. Mater. Res. 83A 2007 1128 1137 (Pubitemid 350231775)
24. A.B. Lansdown, and M.J. Payne An evaluation of the local reaction and biodegradation of calcium sodium alginate (Kaltostat) following subcutaneous implantation in the rat J. R. Coll. Surg. Edinb. 39 1994 284 288
25. O. Smidsrod, and G. Skjakbraek Alginate as immobilization matrix for cells Trends Biotechnol. 8 1990 71 78
26. W.R. Gombotz, and S.F. Wee Protein release from alginate matrices Adv. Drug Deliv. Rev. 64 2012 194 205 (Supplement)
27. R. Deng, K.M. Loyet, S. Lien, S. Iyer, L.E. DeForge, F.P. Theil, H.B. Lowman, P.J. Fielder, and S. Prabhu Pharmacokinetics of humanized monoclonal anti-tumor necrosis factor antibody and its neonatal fc receptor variants in mice and cynomolgus monkeys Drug Metab. Dispos. 38 2010 600 605
28. Y.S. Lin, C. Nguyen, J.L. Mendoza, E. Escandon, D. Fei, Y.G. Meng, and N.B. Modi Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor J. Pharmacol. Exp. Ther. 288 1999 371 378 (Pubitemid 29113511)
29. Y. Vugmeyster, P. Szklut, L. Tchistiakova, W. Abraham, M. Kasaian, and X. Xu Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of humanized monoclonal anti-IL-13 antibodies with different IL-13 neutralization mechanisms Int. Immunopharmacol. 8 2008 477 483
30. H. Schellenkens The Immunogenicity of therapeutic proteins Discov. Med. 9 2010 560 564
31. P.K. Working Potential effects of antibody induction by protein drugs B.L. Ferraiola, M. Mohler, C. Gloff, Protein Pharmacokinetics and, Metabolism 1992 73 92
32. M. Parent, C. Nouvel, M. Koerber, A. Sapin, P. Maincent, and A. Boudier PLGA in situ implants formed by phase inversion: critical physicochemical parameters to modulate drug release J. Control. Release 172 2013 292 304
33. R.B. Patel, L. Solorio, H. Wu, T. Krupka, and A.A. Exner Effect of injection site on in situ implant formation and drug release in vivo J. Control. Release 147 2010 350 358
34. J. Fix Oral controlled release technology for peptides: status and future prospects Pharm. Res. 13 1996 1760 1764 (Pubitemid 27034104)
35. H. Mach, S.M. Gregory, A. Mackiewicz, S. Mittal, A. Lalloo, M. Kirchmeier, and M. Shameem Electrostatic interactions of monoclonal antibodies with subcutaneous tissue Ther. Deliv. 2 2011 727 736
36. Z. Xu, Q. Wang, Y. Zhuang, B. Frederick, H. Yan, E. Bouman-Thio, J.C. Marini, M. Keen, D. Snead, H.M. Davis, and H. Zhou Subcutaneous bioavailability of golimumab at 3 different injection sites in healthy subjects J. Clin. Pharmacol. 50 2010 276 284
37. H.K. Kim, and T.G. Park Microencapsulation of human growth hormone within biodegradable polyester microspheres: protein aggregation stability and incomplete release mechanism Biotechnol. Bioeng. 65 1999 659 667
38. Y. Wei, Y.X. Wang, W. Wang, S.V. Ho, F. Qi, G.H. Ma, and Z.G. Su Microcosmic mechanisms for protein incomplete release and stability of various amphiphilic mPEG-PLA microspheres Langmuir 28 2012 13984 13992